TG Therapeutics TGTX Investment Income Net Amortization Of Discount And Premium
Investment Income Net Amortization Of Discount And Premium at other companies
Other financials
Where this comes from
Reported directly by TG Therapeutics in its filing.
Tagged under the XBRL concept us-gaap:InvestmentIncomeNetAmortizationOfDiscountAndPremium.
The official record: TG Therapeutics’s 10-Q, filed May 6, 2026, on SEC EDGAR. View the filing →
Ask your AI about TG Therapeutics's investment income net amortization of discount and premium.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is TG Therapeutics's investment income net amortization of discount and premium?
- TG Therapeutics (TGTX) reported investment income net amortization of discount and premium of $367K in Q1 2026.
- How has TG Therapeutics's investment income net amortization of discount and premium changed year-over-year?
- TG Therapeutics's investment income net amortization of discount and premium decreased by 72.5% year-over-year, from $1.34M to $367K.
- What is the long-term trend for TG Therapeutics's investment income net amortization of discount and premium?
- Over 3 years (2022 to 2025), TG Therapeutics's investment income net amortization of discount and premium has grown at a 125.4% compound annual growth rate (CAGR), from $331K to $3.79M.
- What does investment income net amortization of discount and premium mean?
- Net interest income earned from investments after adjusting for bond price premiums or discounts.
- How do you interpret investment income net amortization of discount and premium?
- An increase reflects higher returns on cash reserves or a larger investment portfolio.
- How does investment income net amortization of discount and premium compare across companies?
- Varies based on the size of cash reserves and the prevailing interest rate environment.